fda vertex pharmaceuticals

Vertex Stock Jumps

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

MarketWatch · 3h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

CNBC on MSN · 13h

FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

Vertex Stock Jumps After Non-Opioid Painkiller Gets FDA Approval

Shares of Vertex Pharmaceuticals rose 8% in off-hours trading after the pharmaceutical company won U.S. approval for the [first new non-opioid painkiller in decades]( ...

5 things to know for Jan. 31: Plane collision, Confirmation hearings, Pain medicine, Japan sinkhole, FireAid benefit concerts

While America retains a gold standard for airline safety, there are stresses on the US air travel system that have been apparent in a series of near tragedies in recent years. Aviation experts have ...

pharmaphorum1h

Exploring the future: Opportunities and challenges in cell and gene therapy for rare diseases

In this webinar, sponsored by IPG Health, we will explore the role that cell and gene therapies can play in treating rare diseases, the unique challenges faced by pharmaceutical companies, healthcare ...

Vertex Pharmaceuticals price target raised to $435 from $418 at Barclays

Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results